A Study to Evaluate the da Vinci® Xi™ Surgical System in Nipple Sparing Mastectomy (NSM) Procedures
Overview
Tab Title Description
Study type
InterventionalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 21-000213
- Jacksonville, Florida: 21-000213
NCT ID: NCT03892980
Sponsor Protocol Number: ISI dV Xi-NSM
About this study
The purpose of this study is to evaluate the safety and effectiveness of the da Vinci Xi Surgical System in Nipple Sparing Mastectomy procedures.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Subject is female.
- Subject has a BMI ≤ 29.
- Subject is between 18 and 80 years of age.
- Subject is a candidate for a unilateral or bilateral nipple sparing mastectomy procedure with mmediate reconstruction.
- Subject is at increased risk for breast cancer and is seeking prophylactic NSM surgery.
- Subject has no presence of occult cancer as confirmed by physical exam and by preoperative imaging per institution’s guidelines. Known carriers of pathogenic BRCA1/2 mutations should have negative breast MRI.
- Subject has breast ptosis ≤ Grade 2.
- Subject has cup size ≤ C.
- Subject is at low to moderate risk for anesthesia (ASA class I, II or III).
- Subject is willing and able to provide written informed consent.
- Subject is willing and able to comply with the study protocol requirements including follow up examinations up to 5 years (+/- 90 days) post operatively.
Exclusion Criteria:
- Subject has current or prior history of ipsilateral in-situ or invasive breast carcinoma.
- Subject has had previous breast surgery of the ipsilateral breast (excluding needle or core biopsies).
- Subject has an inflammatory and/or infectious skin condition and/or unhealed wounds on the ipsilateral breast.
- Subject has had chemotherapy for contralateral breast cancer within 3 weeks.
- Subject has had previous radiation treatment to the ipsilateral breast/chest area.
- Subject is planned to have other concomitant procedures (oophorectomy, hysterectomy, etc.).
- Subject has a current history of smoking or has smoked within 1 month of screening.
- Subject has hemoglobin A1C levels ≥ 8.
- Subject has a high risk for anesthesia (ASA class ≥ IV) or significant medical comorbidities (i.e., cardiac, pulmonary and neurologic) that preclude longer anesthesia times.
- Subject is contraindicated for general anesthesia or surgery.
- Subject has a known bleeding or clotting disorder.
- Subject is pregnant or suspected to be pregnant or is lactating.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
Mayo Clinic Location |
Status |
Contact |
Rochester, Minn.
Mayo Clinic principal investigator James Jakub, M.D. |
Open for enrollment |
Contact information:
Jennifer Krogman
(507) 538-3320
Krogman.Jennifer@mayo.edu
|
Jacksonville, Fla.
Mayo Clinic principal investigator James Jakub, M.D. |
Open for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
More information
Publications
Publications are currently not available